| Dr Vishad V Sukul, MD | |
|
3601 The Vanderbilt Clinic, Nashville, TN 37232-5100 | |
| (615) 322-3000 | |
| Not Available |
| Full Name | Dr Vishad V Sukul |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 16 Years |
| Location | 3601 The Vanderbilt Clinic, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194985192 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 52611 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Westchester Medical Center | Valhalla, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Westchester Medical Center Advanced Physician Services Pc | 3173660776 | 729 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629008537 PECOS PAC ID: 1759293111 Enrollment ID: O20031125000386 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548290455 PECOS PAC ID: 1759293111 Enrollment ID: O20040309001433 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
| Entity Name | Westchester Medical Center Advanced Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912131392 PECOS PAC ID: 3173660776 Enrollment ID: O20091031000042 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1366872244 PECOS PAC ID: 1759293111 Enrollment ID: O20150618001757 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497921688 PECOS PAC ID: 1759293111 Enrollment ID: O20190320001621 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vishad V Sukul, MD 3601 The Vanderbilt Clinic, Nashville, TN 37232-5100 Ph: (615) 322-3000 | Dr Vishad V Sukul, MD 3601 The Vanderbilt Clinic, Nashville, TN 37232-5100 Ph: (615) 322-3000 |
News Archive
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
"Almost two years after the devastating 7.0 earthquake destroyed much of Port-au-Prince, full recovery appears to be years away," the Miami Herald reports, noting that "thousands of people continue to live in makeshift shelters and tents and rubble from dilapidated buildings still line some streets."
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
Researchers have shown that the number of prescriptions filled out for a treatment associated with improved pregnancy outcomes among individuals with substance use disorder declined in the United States as the coronavirus disease 2019 (COVID-19) pandemic continued.
› Verified 3 days ago
William R Schooley, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 319, Nashville, TN 37203 Phone: 615-986-1256 Fax: 615-320-4106 | |
Judy Corfman, APRN Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Amanda Peltier, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Everette I Howell, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2011 Murphy Ave, Suite 301, Nashville, TN 37203 Phone: 615-327-9543 Fax: 615-341-7583 | |
Reid Thompson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Hong Yu, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: T-4224 Mcn, Vanderbilt Dept Of Neurosurgery, Nashville, TN 37232 Phone: 615-322-5000 | |
Dr. William Edward Gordon, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2011 Murphy Ave, Nashville, TN 37203 Phone: 615-327-9543 |